Bryan, Garnier & Co announces a €14.7m follow-on offering for Amoeba on Euronext with demand from European and US investors

Paris, May 17th 2016 – Bryan, Garnier & Co, the pan-European investment bank for growth companies, announces a successful €14.7m follow-on offering for Amoeba, producer of a biological biocide capable of eliminating waterborne bacterial risks. Bryan, Garnier & Co acted as Global Coordinator, Joint Lead Manager and Bookrunner, strengthening its leadership position in the Cleantech & Renewables sector.
A total of 544,215 new ordinary shares have been issued to qualified and institutional investors in the United States and Europe of which two-thirds are from France and one third is aboard. The new shares represent the maximum 10% capital authorization prior to the private placement. The transaction was oversubscribed with over 40 institutional investors.
The net proceeds from the transaction will be used primarily for financing: i) the acceleration of operations in Europe following (a) the deployment of two production units and (b) the development of the North American market through the implementation of a production unit to facilitate, in particular, the completion of the research and development (R&D) tests in Canada, and ii) general corporate expenses.
Olivier Beaudouin, Partner leading the Cleantech & Renewables franchise, commented: “Amoeba is the top-performing IPO in Europe since January 2015 (+282%). This follow-on offering was substantially oversubscribed with solid, quality demand in France, in Europe and the US. This success demonstrates our commitment to our client on and after their IPO, our international placement capabilities, and strengthens our position as advisor to European Cleantech companies.”
For more information, please contact:
Olivier Beaudouin
Partner –Corporate Finance – Technology & Cleantech
obeaudouin@bryangarnier.com | + 33 1 56 68 75 35
Christian Finan
Director – Equity Capital Markets
cfinan@bryangarnier.com | + 33 1 56 68 75 30
Marc Goudemand
Director – Corporate Finance
mgoudemand@bryangarnier.com | + 33 1 70 36 57 15
About Amoeba
Based in Chassieu – France, AMOEBA develops a biological biocide capable of eliminating waterborne bacterial risk (legionella, pseudomonas, listeria, etc.) This entirely natural solution is presented as an alternative to the chemical treatments traditionally used in the industrial sector. AMOEBA is continuing with its regulatory procedures so as to launch the request for provisional MA in the first half of 2016 for all European countries, as soon as ANSES (French Agency for Food, Environmental and Occupational Health & Safety) has validated AMOEBA’s solution for the “Air Cooled Towers” application. In a worldwide market for chemical biocides, estimated to be worth EUR 21 bn, AMOEBA is today concentrating on the segment of industrial air-cooled towers (ACT) estimated to be worth EUR 1.7 bn. Its disruptive technology complies with new regulations in terms of chemical emissions into the environment. AMOEBA is quoted on compartment C of the Euronext Paris stock exchange and joined the CAC Small index last September 21st. For more information: www.amoeba-biocide.com.